Expression of chemokine receptors upon doxorubicin treatment in breast cancer and sarcoma patients.

Expression of chemokine receptors upon doxorubicin treatment in breast cancer and sarcoma patients. - Chemokine receptors and anthracyclines

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51299

Enrollment

Registered

2022-12-08

Start date

2024-05-27

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer Sarcoma

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Chemotherapy naïve breast cancer and/or sarcoma patients - Receive doxorubicin as standard treatment of care - Age > 18 - Male and female patients - Ability to understand the study and give signed informed consent prior to beginning of protocol specific procedures

Exclusion criteria

Exclusion criteria: If any other treatment is administered earlier to treat the disease, we cannot include the patient.

Design outcomes

Primary

Measure	Time frame
Determine the CXCR1 and CXCR2 expression on immune cells of cancer patients prior and after treatment with doxorubicin.	—

Secondary

Measure	Time frame
Assess the expression of CXCR1 and CXCR2 ligands in the serum of the same patients.	—

Countries

Netherlands

Outcome results